202-CoV
Vaccine candidate against COVID-19
- 1 min read
- 1 chapter
Related on Lably
Through Vaccine
Development
In May 2020, the Bill & Melinda Gates Foundation awarded Shanghai Zerun Biotechnology a $1,000,000 USD vaccine development grant to "support research and development for COVID-19 response".
In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants. As of October 2022, CEPI had provided up to $25.1 million USD towards 202-CoV, but had ceased further funding. The chimeric protein candidate remains in Phase I clinical trials.
More in Health
Food and Drug AdministrationFederal agency of the United States Department of Health and Human ServicesCenters for Disease Control and PreventionUnited States government public health agencyNauseaMedical symptom or conditionSeizurePeriod of symptoms due to excessive or synchronous neuronal brain activityVomitingExpulsion of stomach contents via the mouth or noseIntravenous therapyMedication administered into a vein